IRIS
CARACCIOLO, DANIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.248
AS - Asia 877
EU - Europa 705
SA - Sud America 199
AF - Africa 19
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 3
Totale 3.058
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.209
SG - Singapore 418
IT - Italia 412
CN - Cina 191
BR - Brasile 155
DE - Germania 98
IN - India 89
VN - Vietnam 86
GB - Regno Unito 67
SE - Svezia 35
FI - Finlandia 33
CA - Canada 26
HK - Hong Kong 25
NL - Olanda 14
BD - Bangladesh 12
ID - Indonesia 12
AR - Argentina 11
EC - Ecuador 10
FR - Francia 10
MX - Messico 9
RU - Federazione Russa 9
ZA - Sudafrica 9
JP - Giappone 8
EU - Europa 7
AT - Austria 6
CO - Colombia 5
ES - Italia 5
PY - Paraguay 5
VE - Venezuela 5
CL - Cile 4
JO - Giordania 4
KE - Kenya 4
UZ - Uzbekistan 4
AU - Australia 3
CH - Svizzera 3
CZ - Repubblica Ceca 3
EG - Egitto 3
IQ - Iraq 3
LB - Libano 3
NP - Nepal 3
PK - Pakistan 3
TR - Turchia 3
UA - Ucraina 3
AZ - Azerbaigian 2
ET - Etiopia 2
IR - Iran 2
LT - Lituania 2
OM - Oman 2
PE - Perù 2
PL - Polonia 2
AE - Emirati Arabi Uniti 1
BN - Brunei Darussalam 1
BO - Bolivia 1
EE - Estonia 1
GE - Georgia 1
GR - Grecia 1
GT - Guatemala 1
GY - Guiana 1
JM - Giamaica 1
KG - Kirghizistan 1
KZ - Kazakistan 1
MA - Marocco 1
MY - Malesia 1
PA - Panama 1
RO - Romania 1
SA - Arabia Saudita 1
TT - Trinidad e Tobago 1
Totale 3.058
Salva come PNG Salva come JPEG
Città #
Singapore 192
Chandler 152
Ashburn 119
San Jose 97
Dallas 78
Munich 71
Santa Clara 70
Bengaluru 66
Hefei 66
Chicago 50
London 47
Catanzaro 44
Lawrence 44
Milan 44
Princeton 44
Beijing 42
Ho Chi Minh City 29
Naples 26
Hanoi 23
Hong Kong 22
Turku 22
Wilmington 18
Los Angeles 17
Rome 15
São Paulo 15
New York 14
Des Moines 13
Ottawa 13
Carbonia 12
Parma 12
Brooklyn 11
Helsinki 11
Boardman 9
Cosenza 8
Ercolano 8
Redwood City 8
San Nicola Manfredi 8
Santo Stefano di Rogliano 8
Afragola 7
Boston 6
Melito di Porto Salvo 6
Montreal 6
Reggio Calabria 6
Stockholm 6
Catania 5
Columbus 5
Dhaka 5
Guangzhou 5
Manchester 5
Seattle 5
Settingiano 5
Shanghai 5
The Dalles 5
Amman 4
Brescia 4
Can Tho 4
Charlotte 4
Chennai 4
Da Nang 4
Decollatura 4
Haiphong 4
Hanover 4
Jakarta 4
Jiaxing 4
Johannesburg 4
Mountain View 4
Nairobi 4
New Delhi 4
Pune 4
Redmond 4
Rio de Janeiro 4
Tashkent 4
Thái Bình 4
Acquaviva delle Fonti 3
Ahmedabad 3
Berlin 3
Biên Hòa 3
Cape Town 3
Castrovillari 3
Denver 3
Frankfurt am Main 3
Guayaquil 3
Manaus 3
Mexico City 3
Mileto 3
Nova Iguaçu 3
Nuremberg 3
Olomouc 3
Palermo 3
Paola 3
Phoenix 3
Porto Alegre 3
San Antonio 3
San Francisco 3
Sumaré 3
Tokyo 3
Tongi 3
Treviso 3
Washington 3
6th of October City 2
Totale 1.790
Salva come PNG Salva come JPEG
Nome #
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 123
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 99
miR-22 suppresses DNA ligase III addiction in multiple myeloma 99
A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. 87
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review 83
Distinctive germline expression of class i human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade 78
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 76
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer 71
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 66
Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment 63
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis 63
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 62
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas 62
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 60
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 59
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. (CO-FIRST AUTHOR) 58
Identifying prognostic markers for multiple myeloma through integration and analysis of MMRF-CoMMpass data 58
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin 56
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 56
Allometric scaling approaches for predicting human pharmacokinetic of a locked nucleic acid oligonucleotide targeting cancer-associated miR-221 55
Polymorphic variants in NR1I3 and UGT2B7 predict taxane neurotoxicity and have prognostic relevance in breast cancer patients: a case-control study. 54
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma 53
Mir-221/222 are promising targets for innovative anticancer therapy 53
From single level analysis to multi-omics integrative approaches: A powerful strategy towards the precision oncology 52
Pharmacogenomics biomarker discovery and validation for translation in clinical practice. 52
Mir-22 modulates lenalidomide activity by counteracting myc addiction in multiple myeloma 50
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma 49
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. 49
Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats 49
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: In vitro and in vivo anti-tumor activity 48
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. 48
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives 46
The New Microtubule-Targeting Agent SIX2G Induces Immunogenic Cell Death in Multiple Myeloma 46
Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis 45
Mmrf-commpass data integration and analysis for identifying prognostic markers 45
Distinctive role of the systemic inflammatory profile in non-small-cell lung cancer younger and elderly patients treated with a pd-1 immune checkpoint blockade: A real-world retrospective multi-institutional analysis 45
Integration of DNA Microarray with Clinical and Genomic Data 44
Severe Hemodynamic Instability in a Young Pregnant Woman with Massive Pericardial Effusion and Pulmonary Embolism Secondary to Primary Mediastinal Non-Hodgkin's Lymphoma 43
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity 43
null 43
An unbiased lncRNA dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a novel therapeutic target for multiple myeloma 42
From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario 41
Mirnas and lncrnas as novel therapeutic targets to improve cancer immunotherapy 41
From Single Level Analysis to Multi-Omics Integrative Approaches: A Powerful Strategy towards the Precision Oncology 40
Risk Alleles for Multiple Myeloma Susceptibility in ADME Genes 39
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells (CO-FIRST AUTHOR) 38
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity 37
Alternative non-homologous end-joining: Error-prone dna repair as cancer’s achilles’ heel 37
Frontline therapy CLL without 17p del/p53 aberrations: systematic review and Bayesian network meta-analysis 35
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 35
The potential role of miRNAs in multiple myeloma therapy 32
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells 31
null 31
UMG1/CD3ε-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphoma 30
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma 29
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma. 27
Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma 27
MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches 27
Tools in Pharmacogenomics Biomarker Identification for Cancer Patients 27
TERRA G-quadruplex stabilization behind the anti-multiple myeloma activity: Novel insights about resveratrol pleiotropic effects 25
The potential role of miRNAs in multiple myeloma therapy 25
Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts 24
Synthetic miR-22 impairs NHEJ repair sensistizing multiple myeloma cells to bortezomib-induced BRCAness 21
Immunomodulatory activity of microRNAs: potential implications for multiple myeloma treatment. 20
Targeting oncogenic pri-miR-17-92 in multiple myeloma: molecular findings and therapeutic potential 20
CD19 CAR-T Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Cohort Study from the Calabria Referral Center in Southern Italy 11
Impact of COVID-19 on Hematologic Cancer Patients: Insights From the Late Pandemic Phase 7
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 2
Totale 3.192
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.682
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.682
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202186 0 0 0 0 0 0 11 10 25 20 15 5
2021/2022179 4 0 0 27 7 5 11 30 37 31 24 3
2022/2023541 95 29 32 21 64 38 6 39 76 54 68 19
2023/2024320 86 32 36 22 16 83 7 6 1 5 10 16
2024/2025886 88 26 29 37 59 132 39 45 70 10 130 221
2025/20261.085 111 184 168 227 196 84 115 0 0 0 0 0
Totale 3.192